MX2015016743A - Compuesto de benzotiofeno. - Google Patents

Compuesto de benzotiofeno.

Info

Publication number
MX2015016743A
MX2015016743A MX2015016743A MX2015016743A MX2015016743A MX 2015016743 A MX2015016743 A MX 2015016743A MX 2015016743 A MX2015016743 A MX 2015016743A MX 2015016743 A MX2015016743 A MX 2015016743A MX 2015016743 A MX2015016743 A MX 2015016743A
Authority
MX
Mexico
Prior art keywords
pain
fibromyalgia
osteoarthritic
channel
inflammatory
Prior art date
Application number
MX2015016743A
Other languages
English (en)
Inventor
Nobuaki Takeshita
Kazuhiro Ikegai
Ikumi Kuriwaki
Hiroyuki Hisamichi
Tsukasa Ishihara
Ryuichi Takezawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2015016743A publication Critical patent/MX2015016743A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Problema: Se proporciona un compuesto que es útil como activador del canal de IK1. Medios para la solución: Como resultado de los estudios sobre el activador del canal de IK1, los inventores han descubierto que un compuesto de benzotiofeno muestra efectividad sobre el dolor visceral, dolor inflamatorio, dolor por osteoartritis, dolor neuropático o fibromialgia, con lo cual completa la invención. Un compuesto de la invención tiene un efecto de activación del canal de IK1 y también se puede usar como agente para prevenir y/o tratar el dolor visceral, dolor inflamatorio, dolor por osteoartritis, dolor neuropático o fibromialgia. Además, el activador del canal de IK1 se puede usar como agente para prevenir y/o tratar dolor inflamatorio, dolor por osteoartritis, dolor neuropático y fibromialgia.
MX2015016743A 2013-06-06 2014-06-06 Compuesto de benzotiofeno. MX2015016743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013119416 2013-06-06
PCT/JP2014/065141 WO2014196644A1 (ja) 2013-06-06 2014-06-06 ベンゾチオフェン化合物

Publications (1)

Publication Number Publication Date
MX2015016743A true MX2015016743A (es) 2016-03-21

Family

ID=52005968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016743A MX2015016743A (es) 2013-06-06 2014-06-06 Compuesto de benzotiofeno.

Country Status (31)

Country Link
US (2) US8981119B2 (es)
EP (1) EP3006443B1 (es)
JP (1) JP6314978B2 (es)
KR (1) KR102253721B1 (es)
CN (1) CN105263926B (es)
AR (1) AR096544A1 (es)
AU (1) AU2014275768B2 (es)
BR (1) BR112015030533B1 (es)
CA (1) CA2914606C (es)
CY (1) CY1120341T1 (es)
DK (1) DK3006443T3 (es)
ES (1) ES2671818T3 (es)
HK (1) HK1215570A1 (es)
HR (1) HRP20180722T1 (es)
HU (1) HUE038920T2 (es)
IL (1) IL242800B (es)
LT (1) LT3006443T (es)
MX (1) MX2015016743A (es)
NO (1) NO3006443T3 (es)
PH (1) PH12015502637A1 (es)
PL (1) PL3006443T3 (es)
PT (1) PT3006443T (es)
RS (1) RS57250B1 (es)
RU (1) RU2667507C2 (es)
SG (1) SG11201509989VA (es)
SI (1) SI3006443T1 (es)
TR (1) TR201808724T4 (es)
TW (1) TWI624466B (es)
UA (1) UA117484C2 (es)
WO (1) WO2014196644A1 (es)
ZA (1) ZA201508866B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003357A1 (en) * 2019-07-23 2022-06-01 Astellas Pharma Global Development, Inc. Methods of treating sleep disorders associated with pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614639A (en) * 1995-03-31 1997-03-25 Eli Lilly And Company Process for preparing 2-substituted benzo[b]thiophene compounds and intermediates thereof
US20040116405A1 (en) 2001-02-06 2004-06-17 Brian Cox Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity
WO2003005025A1 (en) * 2001-07-03 2003-01-16 Biovitrum Ab Methods for identifying compounds modulating the activity of ppar-gamma
JP2006522130A (ja) * 2003-04-03 2006-09-28 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール
JP2007523873A (ja) 2003-07-15 2007-08-23 スミスクライン・ビーチャム・コーポレイション 新規化合物
WO2008054435A2 (en) * 2006-01-09 2008-05-08 The Regents Of The University Of California Use of sk channel activators to prevent relapse/reinstatement of drugs of abuse
US8022209B2 (en) 2007-09-12 2011-09-20 Janssen Pharmaceutica Nv Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor
JP5783903B2 (ja) * 2008-11-10 2015-09-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 中間コンダクタンスカルシウム活性化カリウムチャネルを介して細胞間融合を調節するための組成物および方法
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio

Also Published As

Publication number Publication date
US20150133433A1 (en) 2015-05-14
TR201808724T4 (tr) 2018-07-23
AR096544A1 (es) 2016-01-13
RS57250B1 (sr) 2018-07-31
IL242800B (en) 2019-06-30
TW201536775A (zh) 2015-10-01
HK1215570A1 (zh) 2016-09-02
EP3006443A1 (en) 2016-04-13
UA117484C2 (uk) 2018-08-10
PL3006443T3 (pl) 2018-09-28
IL242800A0 (en) 2016-02-01
JP6314978B2 (ja) 2018-04-25
HRP20180722T1 (hr) 2018-06-15
EP3006443B1 (en) 2018-04-25
ZA201508866B (en) 2017-11-29
LT3006443T (lt) 2018-07-10
CA2914606A1 (en) 2014-12-11
PT3006443T (pt) 2018-06-07
ES2671818T3 (es) 2018-06-08
BR112015030533B1 (pt) 2023-02-28
BR112015030533A2 (pt) 2020-10-20
WO2014196644A1 (ja) 2014-12-11
TWI624466B (zh) 2018-05-21
PH12015502637B1 (en) 2016-03-07
SI3006443T1 (en) 2018-08-31
CN105263926A (zh) 2016-01-20
RU2015152150A (ru) 2017-07-13
DK3006443T3 (en) 2018-06-25
RU2667507C2 (ru) 2018-09-21
EP3006443A4 (en) 2016-12-21
US9399038B2 (en) 2016-07-26
AU2014275768A1 (en) 2015-12-17
AU2014275768B2 (en) 2017-12-14
SG11201509989VA (en) 2016-01-28
US8981119B2 (en) 2015-03-17
KR102253721B1 (ko) 2021-05-18
HUE038920T2 (hu) 2018-12-28
CA2914606C (en) 2021-03-23
JPWO2014196644A1 (ja) 2017-02-23
KR20160015281A (ko) 2016-02-12
CY1120341T1 (el) 2019-07-10
US20140364421A1 (en) 2014-12-11
CN105263926B (zh) 2018-05-11
NO3006443T3 (es) 2018-09-22
PH12015502637A1 (en) 2016-03-07

Similar Documents

Publication Publication Date Title
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015017532A (es) Métodos para modular la actividad del regulador de transmembrana de fibrosis quística.
PH12016501099A1 (en) Materials and methods for controlling infections
NZ732799A (en) Picolinamides with fungicidal activity
MX2017000307A (es) Tratamiento de leucemia con inhibidores de histona deacetilasa.
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
PH12016501702B1 (en) Pyrazole amide derivative
MX2017008444A (es) Picolinamidas como fungicidas.
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12016501849A1 (en) 5,6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists
MX2017007188A (es) Compuesto antimicotico.
MX2015009818A (es) Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple.
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
TN2017000047A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2017004819A (es) Metodos de tratamiento de transtornos urológicos usando sarm.
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
PH12015502637A1 (en) Benzothiophene compound
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist
MD4349C1 (ro) Compusul N-(3-metoxifenil)-2-(piridin-2-ilmetilen)-hidrazincarbotioamidă - inhibitor al proliferării celulelor MeW-164 ale melanomului uman
UA92941U (uk) Застосування декаметоксину як протимікробного засобу проти бактерій роду bulkholderia

Legal Events

Date Code Title Description
FG Grant or registration